BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 20682044)

  • 21. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany.
    Ultsch B; Köster I; Reinhold T; Siedler A; Krause G; Icks A; Schubert I; Wichmann O
    Eur J Health Econ; 2013 Dec; 14(6):1015-26. PubMed ID: 23271349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 inactivated varicella-zoster vaccine (ZV
    Eriksson J; Hunger M; Bourhis F; Thorén R; Popmihajlov Z; Finelli L; Jiang Y
    Expert Rev Pharmacoecon Outcomes Res; 2020 Dec; 20(6):613-621. PubMed ID: 31721601
    [No Abstract]   [Full Text] [Related]  

  • 23. Healthcare resource utilization and costs associated with herpes zoster in the US.
    Johnson BH; Palmer L; Gatwood J; Lenhart G; Kawai K; Acosta CJ
    J Med Econ; 2016 Oct; 19(10):928-35. PubMed ID: 27149530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Burden of herpes zoster and post-herpetic neuralgia in Sweden.
    Nilsson J; Cassel T; Lindquist L
    BMC Infect Dis; 2015 May; 15():215. PubMed ID: 26002038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and disease burden of herpes zoster in the population aged ≥50 years in China: Data from an integrated health care network.
    Sun X; Wei Z; Lin H; Jit M; Li Z; Fu C
    J Infect; 2021 Feb; 82(2):253-260. PubMed ID: 33359014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reducing the burden of Herpes Zoster in Italy.
    Gabutti G; Franco E; Bonanni P; Conversano M; Ferro A; Lazzari M; Maggi S; Rossi A; Scotti S; Vitale F; Volpi A; Greco D
    Hum Vaccin Immunother; 2015; 11(1):101-7. PubMed ID: 25483522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan.
    Yaegashi M; Matsui H; Yoshida A; Ban H; Miyazaki R; Oda N; Hattori K; Motomura Y; Usami H; Matsushita H
    Vaccine; 2024 Jan; 42(3):464-470. PubMed ID: 38172019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Burden of herpes zoster and postherpetic neuralgia: Incidence, proportion, and associated costs in the French population aged 50 or over].
    Mick G; Gallais JL; Simon F; Pinchinat S; Bloch K; Beillat M; Serradell L; Derrough T
    Rev Epidemiol Sante Publique; 2010 Dec; 58(6):393-401. PubMed ID: 21094001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measuring the burden of herpes zoster and post herpetic neuralgia within primary care in rural Crete, Greece.
    Lionis CD; Vardavas CI; Symvoulakis EK; Papadakaki MG; Anastasiou FS; Antonopoulou MD; Apostolakis CM; Dimitrakopoulos SA; Fountakis GI; Grammatikopoulos IA; Komninos JD; Kounalakis DK; Ladoukaki ES; Makri KV; Petraki CS; Ploumis NG; Prokopiadou DP; Stefanaki IN; Tsakountakis NA; Tsiligianni IG; Tzortzis EN; Vasilaki AA; Vasilopoulos TK; Vrentzos GE
    BMC Fam Pract; 2011 Dec; 12():136. PubMed ID: 22145678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The humanistic, economic and societal burden of herpes zoster in Europe: a critical review.
    Gater A; Uhart M; McCool R; Préaud E
    BMC Public Health; 2015 Feb; 15():193. PubMed ID: 25880058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health care utilization and cost burden of herpes zoster in a community population.
    Yawn BP; Itzler RF; Wollan PC; Pellissier JM; Sy LS; Saddier P
    Mayo Clin Proc; 2009 Sep; 84(9):787-94. PubMed ID: 19720776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
    Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
    Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
    Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
    J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased Incidence of Herpes Zoster and Postherpetic Neuralgia in Adult Patients following Traumatic Brain Injury: A Nationwide Population-Based Study in Taiwan.
    Tung YC; Tu HP; Tsai WC; Chen CS; Su CH; Shi HY; Lin CL
    PLoS One; 2015; 10(6):e0129043. PubMed ID: 26065420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiology and long-term disease burden of herpes zoster and postherpetic neuralgia in Taiwan: a population-based, propensity score-matched cohort study.
    Lu WH; Lin CW; Wang CY; Chen LK; Hsiao FY
    BMC Public Health; 2018 Mar; 18(1):369. PubMed ID: 29554872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.
    Annemans L; Bresse X; Gobbo C; Papageorgiou M
    J Med Econ; 2010; 13(3):537-51. PubMed ID: 20707768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Burden of herpes zoster and postherpetic neuralgia in Japanese adults 60 years of age or older: Results from an observational, prospective, physician practice-based cohort study.
    Sato K; Adachi K; Nakamura H; Asano K; Watanabe A; Adachi R; Kiuchi M; Kobayashi K; Matsuki T; Kaise T; Gopala K; Holl K
    J Dermatol; 2017 Apr; 44(4):414-422. PubMed ID: 27917531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Herpes zoster vaccine: A health economic evaluation for Switzerland.
    Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M
    Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient.
    Johnson RW; Wasner G; Saddier P; Baron R
    Drugs Aging; 2008; 25(12):991-1006. PubMed ID: 19021299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.
    Szucs TD; Kressig RW; Papageorgiou M; Kempf W; Michel JP; Fendl A; Bresse X
    Hum Vaccin; 2011 Jul; 7(7):749-56. PubMed ID: 21606685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.